Delivering a Diversified Long-term Revenue Stream

Fortress Biotech, Inc. is an innovative biopharmaceutical company focused on delivering a diversified, long-term revenue stream to our shareholders through the creation of a diverse portfolio of marketed products, as well as in-licensing opportunities and through the development of high-potential preclinical and clinical-stage product candidates. Fortress currently has nine marketed products and over 30 programs in development.

Latest Financial Results

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2021

mail icon

Sign Up for Email Alerts

Receive updates straight into your inbox

Sign up today

About Fortress Biotech

Fortress Biotech, Inc. (“Fortress”) is an innovative biopharmaceutical company that was ranked in Deloitte’s 2019 and 2020 Technology Fast 500™, annual rankings of the fastest-growing North American companies in the technology, media, telecommunications, life sciences and energy tech sectors, based on percentages of fiscal year revenue growth over three-year periods. Fortress is focused on acquiring, developing and commercializing high-potential marketed and development-stage pharmaceutical products and product candidates. The company has eight marketed prescription pharmaceutical products and over 30 programs in development at Fortress, at its majority-owned and majority-controlled partners and at partners it founded and in which it holds significant minority ownership positions. Such product candidates span six large-market areas, including oncology, rare diseases and gene therapy, which allow it to create value for shareholders. Fortress advances its diversified pipeline through a streamlined operating structure that fosters efficient drug development. The Fortress model is driven by a world-class business development team that is focused on leveraging its significant biopharmaceutical industry expertise to further expand the company’s portfolio of product opportunities. Fortress has established partnerships with some of the world’s leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including Alexion Pharmaceuticals, Inc., AstraZeneca, City of Hope, Fred Hutchinson Cancer Research Center, St. Jude Children’s Research Hospital and Nationwide Children’s Hospital.

Fortress Biotech at a Glance

30+

Programs in Development

8

Marketed Products

Fortress Biotech Performance

Year over year company performance

As of Dec. 31, 2021 • 10-K 2021

Investor Relations Contacts

Company

Fortress Biotech, Inc.
1111 Kane Concourse
Suite 301
Bay Harbor Islands, FL 33154
info@fortressbiotech.com

Investor Relations

Jaclyn Jaffe
Nicole McCloskey
T: 781-652-4500
ir@fortressbiotech.com

Transfer Agent

VStock Transfer, LLC
18 Lafayette Place
Woodmere, NY 11598
T: 212-828-8436
info@vstocktransfer.com
www.vstocktransfer.com